

Eosinophilic GI Disorder Rates Vary Widely

BY MIRIAM E. TUCKER

NATIONAL HARBOR, MD. — Eosinophilic esophagitis affects an estimated 52/100,000 Americans, while eosinophilic gastritis/colitis affects about 28/100,000, according to the results of the first nationwide study to investigate the disease burden of eosinophilic gastrointestinal disorders.

The study, conducted via an e-mail sur-

vey of pediatric and adult gastroenterologists, demonstrated wide variations in the rates of both EoE and eosinophilic gastritis/eosinophilic colitis (EG/EC) in different parts of the country, with rates highest in the Northeast, followed by the South, the Midwest, and the West. Dr. Wendy M. Book said at the annual meeting of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

Electronic surveys were e-mailed to 10,833 physicians. The total response rate was 17%, including 866 allergy-immunology specialists, 333 pediatric gastroenterologists, and 602 adult gastroenterologists.

Based on the survey responses and U.S. census data, Dr. Book said an estimated 158,705 patients have EoE, with a prevalence of 52.2 per 100,000 population. For EG/EC, the pediatric gastroenterologists

reported seeing an average of 8.9 patients per year, while the adult gastroenterologists reported 5.9 per year, for an estimated 85,281, or 28.1/100,000, said Dr. Book, of the department of internal medicine at Emory University, Atlanta. ■

Disclosures: Dr. Book is president of the nonprofit organization American Partnership for Eosinophilic Disorders. She has no relevant conflicts of interest.



AN AMLODIPINE

a long-acting CCB

TEAM UP WITH TWYNSTA—HELP HYPERTENSIVE PATIENTS ACHIEVE SIGNIFICANT BP REDUCTIONS^{1,2}

All 4 dosage strengths of TWYNSTA[®] (telmisartan/amlodipine) tablets demonstrated significant reductions in cuff DBP and SBP compared to respective individual monotherapies.¹

Study Design: A randomized, double-blind, 8-week, 4 x 4 factorial design trial of Stage-1 and Stage-2 hypertensive patients³ (baseline BP: 153.2/101.7 mmHg) evaluated TWYNSTA vs telmisartan and amlodipine alone (N=1461). The primary endpoint was change in the in-clinic seated trough DBP. SBP/DBP reductions were as follows: -21.0/-16.0 mmHg, TWYNSTA 40/5 mg; -23.8/-19.6 mmHg, TWYNSTA 40/10 mg; -21.6/-17.8 mmHg, TWYNSTA 80/5 mg; -25.8/-19.6 mmHg, TWYNSTA 80/10 mg. Reduction with placebo was -1.6/-5.9 mmHg.^{2†}

[†]According to the JNC 7, Stage-1 hypertension is defined as 140-159 mmHg SBP or 90-99 mmHg DBP. Stage-2 hypertension is ≥ 160 mmHg SBP or ≥ 100 mmHg DBP.³

²Standard deviation was 11.9/7.6 mmHg, TWYNSTA 40/5 mg; 13.2/7.9 mmHg, TWYNSTA 40/10 mg; 12.7/8.5 mmHg, TWYNSTA 80/5 mg; 14.2/7.9 mmHg, TWYNSTA 80/10 mg; 16.7/9.4 mmHg, placebo.²

ARB: Angiotensin receptor blocker. CCB: Calcium channel blocker. DBP: Diastolic blood pressure. SBP: Systolic blood pressure. JNC 7: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

NEW
TWYNSTA[®]
(telmisartan/amlodipine) tablets
40/5 • 40/10 • 80/5 • 80/10 mg



TEAM UP TO HELP CONTROL BP.